Analysts See $-0.05 EPS for Biomerica, Inc. (BMRA)

March 14, 2018 - By Hazel Jackson

 Analysts See $ 0.05 EPS for Biomerica, Inc. (BMRA)
Investors sentiment increased to 0.25 in 2017 Q3. Its up 0.25, from 0 in 2017Q2. It is positive, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 66,682 shares or 11.38% less from 75,249 shares in 2017Q2 were reported.
North Star Inv holds 0% of its portfolio in Biomerica, Inc. (NASDAQ:BMRA) for 250 shares. National Bank Of America De owns 3,832 shares for 0% of their portfolio. Millennium Ltd Liability Com accumulated 0% or 27,023 shares. Malaga Cove Ltd Llc invested 0.03% of its portfolio in Biomerica, Inc. (NASDAQ:BMRA). Wells Fargo And Mn holds 6,500 shares or 0% of its portfolio. Panagora Asset Mgmt has 0% invested in Biomerica, Inc. (NASDAQ:BMRA) for 10,077 shares.

Since January 23, 2018, it had 4 buys, and 0 selling transactions for $65,333 activity. Shares for $49,324 were bought by CANO FRANCIS on Wednesday, January 24.

Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to report $-0.05 EPS on April, 13.They anticipate $0.01 EPS change or 25.00 % from last quarter’s $-0.04 EPS. After having $-0.03 EPS previously, Biomerica, Inc.’s analysts see 66.67 % EPS growth. The stock increased 0.23% or $0.01 during the last trading session, reaching $4.32. About 10,657 shares traded. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since March 14, 2017 and is uptrending. It has outperformed by 49.76% the S&P500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $36.90 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: which released: “Biomerica Inc.” on May 23, 2017, also with their article: “Biomerica: The Next Major IBS Product” published on September 02, 2016, published: “Biomerica Inc. BMRA (US: Nasdaq)” on February 27, 2011. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: and their article: “Biomerica Commences Clinical Studies for New Gastroenterology H. Pylori Test” published on September 12, 2017 as well as‘s news article titled: “Biomerica’s colorectal screening test OK’d in China” with publication date: January 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.